Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of The Chemours Company (NYSE:CC – Get Rating) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 28,533 shares of the specialty chemicals company’s stock, valued at approximately $703,000.
Several other hedge funds have also added to or reduced their stakes in the business. Raymond James & Associates raised its stake in shares of Chemours by 31.0% in the 1st quarter. Raymond James & Associates now owns 135,617 shares of the specialty chemicals company’s stock valued at $4,269,000 after purchasing an additional 32,121 shares during the period. Cetera Advisor Networks LLC increased its position in shares of Chemours by 21.3% in the first quarter. Cetera Advisor Networks LLC now owns 9,636 shares of the specialty chemicals company’s stock valued at $303,000 after acquiring an additional 1,695 shares during the last quarter. Bank of Montreal Can increased its position in shares of Chemours by 36.4% in the first quarter. Bank of Montreal Can now owns 73,197 shares of the specialty chemicals company’s stock valued at $2,361,000 after acquiring an additional 19,552 shares during the last quarter. D.A. Davidson & CO. acquired a new stake in shares of Chemours in the first quarter valued at about $208,000. Finally, MetLife Investment Management LLC increased its position in shares of Chemours by 35.7% in the first quarter. MetLife Investment Management LLC now owns 107,133 shares of the specialty chemicals company’s stock valued at $3,373,000 after acquiring an additional 28,160 shares during the last quarter. Institutional investors and hedge funds own 71.89% of the company’s stock.
Chemours Stock Performance
Shares of Chemours stock opened at $34.18 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.70 and a debt-to-equity ratio of 3.24. The Chemours Company has a twelve month low of $22.56 and a twelve month high of $44.95. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 9.57, a P/E/G ratio of 1.29 and a beta of 1.88. The company’s fifty day moving average is $33.39 and its 200 day moving average is $31.84.
Chemours Announces Dividend
Analysts Set New Price Targets
A number of analysts recently issued reports on the company. The Goldman Sachs Group lifted their target price on Chemours from $34.00 to $38.00 and gave the company a “neutral” rating in a research report on Tuesday, February 14th. Credit Suisse Group lifted their price target on Chemours from $24.00 to $27.00 and gave the stock an “underperform” rating in a report on Friday, February 10th. Citigroup lifted their price target on Chemours from $33.00 to $35.00 and gave the stock a “neutral” rating in a report on Monday, February 13th. Bank of America upgraded Chemours from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $37.00 to $40.00 in a report on Wednesday, January 11th. Finally, Royal Bank of Canada lifted their price target on Chemours from $33.00 to $36.00 and gave the stock a “sector perform” rating in a report on Monday, February 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $36.33.
Chemours Company Profile
The Chemours Co is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial.
Featured Articles
- Get a free copy of the StockNews.com research report on Chemours (CC)
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC – Get Rating).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
